KC
ALXN

Kellner Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Kellner Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-130,478
Closed -$24M – 33
2021
Q2 		$24M Buy
130,478
+37,628
+41% +$6.46M 7.35% 3
2021
Q1 		$14.2M Buy
92,850
+65,750
+243% +$10.2M 5.15% 8
2020
Q4 		$4.23M Buy
+27,100
New +$3.48M 2.23% 14

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Kellner Capital's ALXN Position: Q3 2021 in Review

Kellner Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 130,478 shares — an estimated $24M sold.

Kellner Capital first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $24M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Kellner Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Kellner Capital sold 130,478 Alexion Pharmaceuticals shares in Q3 2021, an estimated $24M.
  • Kellner Capital first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Kellner Capital's Alexion Pharmaceuticals position peaked at $24M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Kellner Capital's 13F filing for Q3 2021, filed 10 Nov 2021.